Renaissance Capital logo

CVKD News

Renaissance Capital's January IPO Market Update

Cadrenal Therapeutics logo

Following the challenges of the prior year, the 2023 IPO market started off strong with the Renaissance IPO Index climbing 16%, more...read more

US IPO Weekly Recap: Just one small IPO begins trading as the pipeline grows

QSG

Just one small IPO began trading this week as headline deal QuantaSing Group (QSG) delayed its offering; it now plans to price in the week ahead. The pipeline continued to see more activity, with six IPOs submitting initial filings, including...read more

Thrombosis and AFib biotech Cadrenal Therapeutics prices IPO at $5

Cadrenal Therapeutics logo

Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, raised $7 million by offering 1.4 million shares at $5, as expected. The company originally planned to offer 2 million shares before lowering the proposed...read more

Thrombosis and AFib biotech Cadrenal Therapeutics lowers proposed share offering by 30% ahead of $7 million IPO

Cadrenal Therapeutics logo

Cadrenal Therapeutics, a Phase 3-ready biotech developing an acquired therapy for thrombosis and AFib, lowered the proposed deal size for its upcoming IPO on Tuesday. The Ponte Vedra, FL-based company now plans to raise $7 million by offering 1.4 million shares...read more